ES2149167T3 - Factor transformante del crecimiento tipo beta. - Google Patents

Factor transformante del crecimiento tipo beta.

Info

Publication number
ES2149167T3
ES2149167T3 ES92900433T ES92900433T ES2149167T3 ES 2149167 T3 ES2149167 T3 ES 2149167T3 ES 92900433 T ES92900433 T ES 92900433T ES 92900433 T ES92900433 T ES 92900433T ES 2149167 T3 ES2149167 T3 ES 2149167T3
Authority
ES
Spain
Prior art keywords
beta
tgf
protein
reduced
beta type
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92900433T
Other languages
English (en)
Inventor
Yasushi Owaga
David Schmidt
James Dasch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celtrix Pharmaceuticals Inc
Original Assignee
Celtrix Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celtrix Pharmaceuticals Inc filed Critical Celtrix Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2149167T3 publication Critical patent/ES2149167T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/12—Growth hormone, growth factor other than t-cell or b-cell growth factor, and growth hormone releasing factor; related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

SE DESCRIBE UNA NUEVA FORMA HETERODIMERICA DEL TGF-(BETA). ESTA MOLECULA KD 25 ES ACTIVA EN ENSAYOS IN VITRO EN LA INHIBICION DEL CRECIMIENTO DE LAS CELULAS EPITELIALES. LA PROTEINA PUEDE AISLARSE A PARTIR DEL HUESO. CUANDO SE REDUCE, LA PROTEINA SE LEVIGA EN DOS PICOS MEDIANTE RP-HPLC. LA PROTEINA REDUCIDA A PARTIR DEL PICO DE LEVIGACION MAS TEMPRANO REACCIONA PREDOMINANTEMENTE CON LOS ANTICUERPOS DIRIGIDOS CONTRA EL TGF-(BETA)3, MIENTRAS QUE LA PROTEINA REDUCIDA A PARTIR DEL PICO DE LEVIGACION POSTERIOR REACCIONA PREDOMINANTEMENTE CON LOS ANTICUERPOS DIRIGIDOS CONTRA EL TGF-(BETA)2. LA SECUENCIA DE AMINOACIDO DE TERMINAL N Y LA INMUNOREACTIVIDAD DE LA PROTEINA NATIVA SON CONSISTENTES CON UN HETERODIMERO DEL TGF-(BETA)2 Y DEL TGF-(BETA)3.
ES92900433T 1990-11-16 1991-11-18 Factor transformante del crecimiento tipo beta. Expired - Lifetime ES2149167T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61430690A 1990-11-16 1990-11-16
PCT/US1991/008606 WO1992008480A1 (en) 1990-11-16 1991-11-18 A β-TYPE TRANSFORMING GROWTH FACTOR

Publications (1)

Publication Number Publication Date
ES2149167T3 true ES2149167T3 (es) 2000-11-01

Family

ID=24460682

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92900433T Expired - Lifetime ES2149167T3 (es) 1990-11-16 1991-11-18 Factor transformante del crecimiento tipo beta.

Country Status (9)

Country Link
US (1) US5462925A (es)
EP (1) EP0557418B1 (es)
JP (1) JPH06505965A (es)
AT (1) ATE194169T1 (es)
AU (1) AU660635B2 (es)
CA (1) CA2096441A1 (es)
DE (1) DE69132275T2 (es)
ES (1) ES2149167T3 (es)
WO (1) WO1992008480A1 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPN271295A0 (en) * 1995-05-02 1995-05-25 Gropep Pty Ltd Method of treatment
US6077823A (en) * 1991-03-11 2000-06-20 Creative Biomolecules, Inc. Method for reducing tissue damage associated with ischemia-reperfusion or hypoxia injury
US6194376B1 (en) * 1991-03-11 2001-02-27 Creative Biomolecules, Inc. Method for modulating inflammatory response comprising administering morphogen
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6251920B1 (en) 1993-05-13 2001-06-26 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6306421B1 (en) 1992-09-25 2001-10-23 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
AU5405494A (en) * 1992-10-30 1994-05-24 Genentech Inc. Method for preventing or treating liver disease
US5981568A (en) 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
DE69435137D1 (de) * 1993-05-13 2008-10-16 Poniard Pharmaceuticals Inc Prävention und behandlung von pathologien, die mit einer abnormalen proliferationglatter muskelzellen verbunden sind
JPH11510479A (ja) * 1995-06-07 1999-09-14 ネオルックス コーポレイション タモキシフェン類似体による心臓血管疾病の予防及び治療
EP1980246A1 (en) * 1995-06-07 2008-10-15 Poniard Pharmaceuticals, Inc. Prevention and treatment of cardiovascular pathologies with tamoxifen analogues
DE69740089D1 (de) 1996-03-22 2011-02-10 Stryker Corp Verfahren zur verbesserten funktionellen Erholung der motorischen Koordiination, der Sprache oder der Sinneswahrnehmung nach Trauma oder Ischämie des ZNS
US6846906B1 (en) * 1998-10-07 2005-01-25 Stryker Corporation Modified proteins of the TGF-β superfamily, including morphogenic proteins
US7378432B2 (en) * 2001-09-14 2008-05-27 Tel Aviv University Future Technology Development L.P. Glycogen synthase kinase-3 inhibitors
JP2007525188A (ja) 2003-05-16 2007-09-06 インターミューン インコーポレイテッド 合成ケモカイン受容体リガンドおよびその使用方法
ES2468516T3 (es) 2003-10-06 2014-06-16 Paranta Biosciences Limited Folistatina para usar en la regulaci�n negativa de una respuesta inflamatoria
AU2005230848B9 (en) * 2004-03-31 2011-06-02 Genentech, Inc. Humanized anti-TGF-beta antibodies
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
TWI747816B (zh) * 2015-03-05 2021-12-01 紐西蘭商奧克蘭聯合服務有限公司 眼用組合物用於製備藥物的用途
MX2018014047A (es) 2016-05-17 2019-06-20 Genentech Inc Firmas de genes estromales para el diagnóstico y uso en inmunoterapia.
EP3707510B1 (en) 2017-11-06 2024-06-26 F. Hoffmann-La Roche AG Diagnostic and therapeutic methods for cancer
WO2023080900A1 (en) 2021-11-05 2023-05-11 Genentech, Inc. Methods and compositions for classifying and treating kidney cancer
WO2024077095A1 (en) 2022-10-05 2024-04-11 Genentech, Inc. Methods and compositions for classifying and treating bladder cancer
WO2024077166A1 (en) 2022-10-05 2024-04-11 Genentech, Inc. Methods and compositions for classifying and treating lung cancer

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5115625A (ja) * 1974-07-26 1976-02-07 Hokko Chem Ind Co Shushishodokuzai
JPS5333738U (es) * 1976-08-31 1978-03-24
JPS58121932A (ja) * 1982-01-12 1983-07-20 太田　孝治 チユ−ブ搾り装置
DE3382562D1 (de) * 1982-09-24 1992-06-25 Us Health Wiederherstellung von gewebe bei tieren.
JPS6034997A (ja) * 1983-05-09 1985-02-22 ジヨージ、ジヨセフ、トダロ 生物学的活性ポリペプチド類
US4843063A (en) * 1984-07-16 1989-06-27 Collagen Corporation Polypeptide cartilage-inducing factors found in bone
US4886747A (en) * 1985-03-22 1989-12-12 Genentech, Inc. Nucleic acid encoding TGF-β and its uses
US4806523A (en) * 1985-08-06 1989-02-21 Collagen Corporation Method of treating inflammation
US4931548A (en) * 1987-01-30 1990-06-05 Techne Corporation Heterodimer form of transforming growth factor-beta
WO1990000900A1 (en) * 1988-07-20 1990-02-08 Amgen Inc. Method of treating inflammatory disorders by reducing phagocyte activation

Also Published As

Publication number Publication date
US5462925A (en) 1995-10-31
EP0557418A4 (en) 1994-09-14
CA2096441A1 (en) 1992-05-17
AU9046791A (en) 1992-06-11
AU660635B2 (en) 1995-07-06
JPH06505965A (ja) 1994-07-07
DE69132275T2 (de) 2001-01-25
WO1992008480A1 (en) 1992-05-29
EP0557418B1 (en) 2000-06-28
ATE194169T1 (de) 2000-07-15
DE69132275D1 (de) 2000-08-03
EP0557418A1 (en) 1993-09-01

Similar Documents

Publication Publication Date Title
ES2149167T3 (es) Factor transformante del crecimiento tipo beta.
PH20343A (en) Cysteline-depleted muteins of biologically active proteins
DE69016655D1 (de) Biologisch aktive polypeptide, die auf transformierten wachstumsfaktor-beta-sequenzen basieren.
DE69129803D1 (de) Wasserlösliche peptidanaloguen mit bindungstellen
NZ330897A (en) Human trk receptors and neurotropic factor inhibitors
ES8802235A1 (es) Procedimiento para preparar un polipeptido
ES2147558T3 (es) Nuevos polipeptidos para promover la fijacion celular.
ATE120374T1 (de) Markierte polypeptidderivate.
HUP0002704A2 (hu) Az 5. és a 6. helyzetben módosított GnRH antagonisták
DE69027533D1 (de) Heilmittelpeptide
ATE168719T1 (de) Osteogene peptide
ES2089029T3 (es) Produccion de factor de crecimiento similar a la insulina i biologicamente activo a partir de sistemas de celulas hospedantes de expresion elevada.
ATE282634T1 (de) Chaperonin 10
DK0592566T3 (da) IL-6-muteiner med reduceret cysteinantal
GR3019836T3 (en) Protein anti-cancer agent
EP0356107A3 (en) Proteins having growth hormone anabolic properties with reduced effect on carbohydrate metabolism
ATE110390T1 (de) Wachstumsfaktor-rezeptor.
ES2044928T3 (es) Enzima alfa-amidante en terminal c y procedimiento para la produccion y el uso del mismo.
WO1992006199A3 (fr) Peptides inducteurs d'anticorps inhibant des retrovirus du type hiv et anticorps diriges contre ces peptides
ATE20669T1 (de) Antigene lineare peptidverbindungen.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 557418

Country of ref document: ES